Abstract:<h3 class="Heading">Purpose</h3><p class="Para">Hepatocellular carcinoma (HCC) is a common cancer worldwide, and complete surgical resection of diseased tissue is a reliable strategy to cure cancer. Fluorescence image-guided surgery is a promising tool for surgeons to identify and remove malignant lesions. While non-targeted fluorescent dyes have been used for HCC diagnosis and resection, insufficient specificity and false positive uptake from inflammatory tissue result in a high recurrence rate or excessive excision of healthy liver tissue. To circumvent these problems, we focused on developing novel tumor-specific targeting probe to selectively illuminate cancer region during surgery. Given overexpression of histone deacetylases (HDACs) in HCC and many other cancers, HDAC-targeted imaging has been emerged as a promising tool for tumor detection.</p><h3 class="Heading">Procedures</h3><p class="Para">Recently, high expression of HDACs, in particular HDAC6, has been observed in tumor samples of HCC patient, and a few HDAC inhibitors, including FDA-approved suberoylanilide hydroxamic acid (SAHA), display potent antitumor effect on HCC. Correspondingly, in this study, we utilized a small molecule SAHA with the high HDAC-binding affinity as the HCC-specific targeting ligand to develop HDAC-targeted fluorescence probe for HCC detection and fluorescence image-guided resection.</p><h3 class="Heading">Results</h3><p class="Para">In <em class="EmphasisTypeItalic">in vitro</em> imaging, SAHA was labelled with fluorescein isothiocyanate (FITC) to evaluate targeting property, and the imaging results demonstrated that FITC-SAHA was specific uptake by HCC Bel-7402 cells. In <em class="EmphasisTypeItalic">in vivo</em> imaging, near infrared fluorescence dye IRDye800CW-labelled SAHA (NIR probe IRDye800CW-SAHA) showed rapid tumor accumulation with high tumor-to-background contrast on both the subcutaneous and orthotopic HCC mouse tumor models. Furthermore, the orthotopic HCC was successfully resected by the IRDye800CW-SAHA fluorescence image<strong class="EmphasisTypeBold">-</strong>guided surgery. Moreover, IRDye800CW-SAHA showed no toxicity toward healthy tissues.</p><h3 class="Heading">Conclusions</h3><p class="Para">Our results indicate that IRDye800CW-SAHA is a clinical translatable probe for HCC detection and resection.</p>

Recent advances in HDAC-targeted imaging probes for cancer detection

HDAC-targeting epigenetic modulators for cancer immunotherapy

New Development of HDAC Inhibitors As Anti-Cancer Agents

Advances in targeting histone deacetylase for treatment of solid tumors

Targeting histone deacetylases for cancer therapy: Trends and challenges

Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices

Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)

Recent Development on Peptide-Based Probes for Multifunctional Biomedical Imaging

A novel highly sensitive fluorescent probe for bioimaging biothiols and its applications in distinguishing cancer cells from normal cells.

Small‐Molecule Fluorescent Probes for Detecting HDAC Activity

HDAC11: A novel target for improved cancer therapy

Live intraoperative diagnosis of hepatic metastasis via HDACs targeting molecular theranostic agent

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode

HDAC-an important target for improving tumor radiotherapy resistance